Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial'. Together they form a unique fingerprint.